Sepracor Inc. is a research-based pharmaceutical company dedicated to treating and preventing human disease by discovering, developing, and commercializing innovative pharmaceutical products that are directed toward serving unmet medical needs. Sepracor's drug development program has yielded a portfolio of pharmaceutical products and candidates with a focus on the treatment of respiratory and central nervous system disorders. Sepracor's commercialization efforts are carried out by its U.S.-based, primary care and specialty-oriented sales force, which is comprised of approximately 1,500 sales professionals, as well as through out-licensing partnerships. (levalbuterol HCl) Inhalation Solution, both of which are indicated for the treatment or prevention of bronchospasm in patients with reversible obstructive airway disease. In December 2005, Sepracor submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for arformoterol tartrate inhalation solution, a long-acting beta-agonist formulation for long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). The NDA for arformoterol tartrate has been filed and is under formal review by the FDA. Sepracor has several additional compounds in early stages of development that are directed principally toward central nervous system disorders.
This article uses content from http://www.AboutUs.org
